Cascara sagrada laxatives
This article was originally published in The Tan Sheet
Executive Summary
CDER Ombudsman James Morrison should "intercede and facilitate" a meeting between AHPA, Division of OTC Drug Products to discuss data on cascara sagrada, trade group says in Sept. 12 letter. OTC division denied association's earlier request to discuss May 9 final rule classifying ingredient as Category II in OTC laxative products. AHPA also has asked FDA to stay rule's Nov. 5 effective date (1"The Tan Sheet" June 17, 2002, p. 7). Separate petition submitted by Arnall Golden & Gregory (Atlanta) requests that FDA withhold enforcement action against manufacturers of cascara sagrada laxatives pending publication of laxatives final monograph. Petition also suggests FDA could consider "imposing certain labeling restrictions relating to the product's use" to keep such laxatives on the market...
You may also be interested in...
Aloe Definition Clarification In Laxatives Final Rule Requested By AHPA, IASC
FDA's final rule on aloe and cascara sagrada does not properly distinguish between aloe used in OTC drug laxatives and aloe vera gel used in foods and dietary supplements, AHPA and the International Aloe Science Council say in a 1citizen petition
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.